Business Description
Annexin Pharmaceuticals AB
ISIN : SE0009664154
Compare
Compare
Traded in other countries / regions
ANNX.SwedenQ91.Germany IPO Date
2017-04-19Description
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 1.58 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.7 | |||||
| 3-Year EPS without NRI Growth Rate | 12.5 | |||||
| 3-Year FCF Growth Rate | 8.8 | |||||
| 3-Year Book Growth Rate | -29.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.27 | |||||
| 9-Day RSI | 55.91 | |||||
| 14-Day RSI | 54.82 | |||||
| 6-1 Month Momentum % | -34.03 | |||||
| 12-1 Month Momentum % | -59.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.83 | |||||
| Quick Ratio | 1.83 | |||||
| Cash Ratio | 1.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -404.94 | |||||
| ROA % | -227.52 | |||||
| ROIC % | -560.6 | |||||
| ROC (Joel Greenblatt) % | -3891.32 | |||||
| ROCE % | -403.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 15.16 | |||||
| Price-to-Tangible-Book | 13.65 | |||||
| EV-to-EBIT | -1.87 | |||||
| EV-to-EBITDA | -1.87 | |||||
| EV-to-FCF | -1.92 | |||||
| Price-to-Net-Current-Asset-Value | 27.3 | |||||
| Price-to-Net-Cash | 27.3 | |||||
| Earnings Yield (Greenblatt) % | -53.4 | |||||
| FCF Yield % | -47.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annexin Pharmaceuticals AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.154 | ||
| Beta | 0 | ||
| Volatility % | 44.62 | ||
| 14-Day RSI | 54.82 | ||
| 14-Day ATR (kr) | 0.022089 | ||
| 20-Day SMA (kr) | 0.2632 | ||
| 12-1 Month Momentum % | -59.99 | ||
| 52-Week Range (kr) | 0.183571 - 0.723986 | ||
| Shares Outstanding (Mil) | 346.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annexin Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annexin Pharmaceuticals AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Annexin Pharmaceuticals AB Frequently Asked Questions
What is Annexin Pharmaceuticals AB(OSTO:ANNX)'s stock price today?
The current price of OSTO:ANNX is kr0.27. The 52 week high of OSTO:ANNX is kr0.72 and 52 week low is kr0.18.
When is next earnings date of Annexin Pharmaceuticals AB(OSTO:ANNX)?
The next earnings date of Annexin Pharmaceuticals AB(OSTO:ANNX) is 2024-07-18.
Does Annexin Pharmaceuticals AB(OSTO:ANNX) pay dividends? If so, how much?
Annexin Pharmaceuticals AB(OSTO:ANNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers